文献速递腹部US

Sonazoid与SonoVue超声造影诊断肝细胞癌的个体内比较

Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2024-04-07

前瞻性研究纳入113例肝癌高危患者共115个肝脏病灶,行Sonazoid超声造影与SonoVue超声造影,按CEUS LI-RADS v2017及改良标准分类,结果显示两者诊断肝癌的敏感度和特异度相近,Sonazoid联合Kupffer期缺损未显著提高诊断效能。

要点

  • CEUS LI-RADS v2017下Sonazoid与SonoVue诊断肝癌敏感度71.3% vs 72.3%、特异度85.7% vs 81.0%,效能非劣。
  • 改良CEUS LI-RADS(Kupffer期缺损替代晚期轻度廓清)未显著提高Sonazoid诊断效能。
  • 两种造影剂对所有观察的一致性为0.610,对肝癌的一致性为0.452。

核心结论

  • 按LI-RADS v2017,Sonazoid与SonoVue超声造影评估肝癌病灶效能非劣,且加入Kupffer期缺损未显著提高Sonazoid诊断效能。

研究设计与样本

  • 前瞻性研究,2020年10月至2022年5月,纳入113例肝癌高危患者共115个病灶,均经临床或病理确诊,分别按CEUS LI-RADS v2017及改良CEUS LI-RADS分类比较两种造影剂诊断效能。

关键影像表现/征象

  • 分析115个肝脏病灶,其中肝癌94个、非肝癌恶性肿瘤12个、良性病灶9个。
  • 比较两种造影剂的血管期与Kupffer期影像特征。

诊断标准与关键数值

  • CEUS LI-RADS v2017:SonoVue敏感度71.3%、特异度85.7%;Sonazoid敏感度72.3%、特异度81.0%。
  • 改良CEUS LI-RADS(Kupffer期缺损替代晚期轻度廓清):Sonazoid敏感度73.4%、特异度81.0%,与v2017的72.3%和81.0%相当。
  • 两种造影剂对所有观察的一致性为0.610(95%CI 0.475, 0.745),对肝癌的一致性为0.452(95%CI 0.257, 0.647)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess whether the diagnostic performance of Sonazoid contrast-enhanced ultrasound (SZUS) is non-inferior to that of SonoVue contrast-enhanced ultrasound (SVUS) in diagnosing hepatocellular carcinoma (HCC) in individuals with high risk.

MATERIALS AND METHODS: This prospective study was conducted from October 2020 to May 2022 and included participants with a high risk of HCC who underwent SZUS and SVUS. All lesions were confirmed by clinical or pathological diagnosis. Each nodule was classified according to the Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System version 2017 (CEUS LI-RADS v2017) for SVUS and SZUS and the modified CEUS LI-RADS (using Kupffer phase defect instead of late and mild washout) for SZUS. The diagnostic performance of both two modalities for all observations was compared. Analysis of the vascular phase and Kupffer phase imaging characteristics of CEUS was performed.

RESULTS: One hundred and fifteen focal liver lesions from 113 patients (94 HCCs, 12 non-HCC malignancies, and 9 benign lesions) were analysed. According to CEUS LI-RADS (v2017), SVUS and SZUS showed similar sensitivity (71.3% vs. 72.3%) and specificity (85.7% vs. 81.0%) in HCC diagnosis. However, the modified CEUS LI-RADS did not significantly improve the diagnostic efficacy of Sonazoid compared to CEUS LI-RADS v2017, having equivalent sensitivity (73.4% vs. 72.3%) and specificity (81.0% vs. 81.0%). The agreement between SVUS and SZUS for all observations was 0.610 (95% CI 0.475, 0.745), while for HCCs it was 0.452 (95% CI 0.257, 0.647).

CONCLUSION: Using LI-RADS v2017, SZUS and SVUS showed non-inferior efficacy in evaluating HCC lesions. In addition, adding Kupffer phase defects to SZUS does not notably improve its diagnostic efficacy.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Guo D, Wan W, Bai X, et al. Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma. Abdom Radiol (NY). 2024. PMID: 38584190. doi:10.1007/s00261-024-04250-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。